Aditya Bardia, MD, MPH

Articles

Elacestrant real-world progression-free survival (rwPFS) of adult patients with ER+/HER2-, advanced breast cancer: a retrospective analysis using insurance claims in the United States

December 18th 2024

Dr. Aditya Bardia presents real-world findings on elacestrant, demonstrating prolonged real-world progression-free survival (rwPFS) in ER+/HER2- advanced breast cancer patients across all clinically relevant subgroups, with benefits observed particularly in earlier treatment lines and in those without prior fulvestrant exposure.

Dr Bardia on T-DXd Efficacy By Pace of Prior CDK4/6 Inhibitor Progression in Breast Cancer

December 11th 2024

Aditya Bardia, MD, MPH, FASCO, discusses the efficacy of T-DXd in HER2-low/ultralow metastatic breast cancer by disease progression on prior therapy.

Dr Bardia on Findings From DESTINY-Breast06 in HER2-Low Breast Cancer

November 6th 2024

Aditya Bardia, MD, MPH, FASCO, discusses QOL outcomes among patients with HER2-low and HER2-ultralow breast cancer from the DESTINY-Breast06 trial.

Key Takeaways and Clinical Practice Pearls in the Treatment of Patients with Breast Cancer Receiving ADCs

October 2nd 2024

Panelists discuss how addressing unmet needs in patient selection, resistance mechanisms, and long-term outcomes can enhance the efficacy of antibody-drug conjugates in breast cancer treatment.

Expert Insights: Investigational ADCs Safety Profiles

September 25th 2024

Panelists discuss how, despite the investigational status of agents like patritumab deruxtecan (HER3-DXd) and datopotamab deruxtecan (Dato-DXd), it’s crucial for community oncologists to be aware of the treatment-related adverse effects (TRAEs) associated with these therapies and to consider effective management strategies as reported in clinical trials.

Future Perspectives on ADCs in Breast Cancer

September 24th 2024

Panelists discuss how ongoing clinical trials of investigational antibody-drug conjugates (ADCs) are advancing treatment options for breast cancer, particularly in patients with active brain metastases and advanced disease.

Role of Multidisciplinary Team in the Management of Patients Receiving ADCs in Breast Cancer

September 18th 2024

Panelists discuss how the multidisciplinary team plays a crucial role in managing treatment-resistant adverse effects for patients receiving antibody-drug conjugates, emphasizing collaboration among oncologists, pharmacists, nurses, and specialists to optimize patient care and ensure comprehensive support.

Expert Perspectives: T-DM1 Adverse Events Overview and Management Strategies

September 18th 2024

Panelists discuss how management and monitoring for pneumonitis and cardiotoxicity in trastuzumab deruxtecan (T-DXd) is similar to trastuzumab emtansine (T-DM1), while also emphasizing the need for awareness of adverse effects such as peripheral neuropathy, thrombocytopenia, and hepatotoxicity, along with strategies for their management and when to consider therapy modifications.

Clinical Management Considerations: Pneumonitis associated with T-DXd

September 11th 2024

Experts on breast cancer provide clinical insights on the management of pneumonitis associated with trastuzumab deruxtecan.

Overview of Cardiotoxicity Risk with T-DXd and Monitoring Strategies along with Anti-Nausea strategies

September 11th 2024

Experts on breast cancer discuss the potential adverse events related to trastuzumab deruxtecan (T-DXd).

Expert Insights: SG Adverse Events Management including Alopecia & Nausea

September 4th 2024

Panelists discuss how to manage side effects of sacituzumab govitecan (SG), including counseling on alopecia, proactive management strategies, routine antiemetic premedications, and adjustments for chemotherapy-induced nausea and vomiting, as well as recommended breakthrough antinausea medications for home use.

Navigating SG-related Diarrhea

September 4th 2024

Panelists discuss how to manage sacituzumab govitecan therapy, including absolute neutrophil count cutoffs for dose adjustments, handling febrile neutropenia, comparing diarrhea rates to clinical trials, identifying risk factors, and strategies for managing SG-related diarrhea.

Expert Perspectives on the Management of SG-Related Neutropenia

August 28th 2024

This discussion focuses on strategies to manage neutropenia associated with SG, including the use of prophylactic growth factors and timing of their administration, comparing management approaches between clinicians.

Overview of SG-Related Neutropenia Rates in Real-Life Setting and in Clinical Trials

August 28th 2024

This discussion explores the occurrence and risk factors of neutropenia associated with SG treatment, comparing clinical practice experiences with trial data.

ADCs in Breast Cancer: Mechanism of Action, and Components

August 21st 2024

Medical experts discuss the distinct mechanisms and components of different antibody-drug conjugates (ADCs), including the drug, antibody, and linker, and how these components contribute to the mechanisms of ADC-related toxicities.

Overview of Current ADCs in Breast Cancer

August 21st 2024

Medical experts review the currently available antibody-drug conjugates for breast cancer, including Sacituzumab govitecan (Trop-2 directed ADC), Kadcyla (ado-trastuzumab emtansine, T-DM1, HER2-directed ADC), and Enhertu (fam-trastuzumab deruxtecan-nxki, T-DXd, HER2-directed ADC).

Unmet Needs and Future Direction in HER2+ Breast Cancer

July 29th 2024

The panel looks to the future landscape for HER2+ breast cancer, highlighting emerging treatment practices and currently unmet needs.

Clinical Considerations and Subsequent Therapies or Sequencing in HER2-Low/HER2+ mBC

July 29th 2024

Focusing on the selection of subsequent therapies for patients with HER2-low/HER2+ metastatic breast cancer, the panel discusses treatment sequencing considerations and practices.

Clinical Perspectives on Managing ILD Related to T-DXd

July 22nd 2024

Breast cancer specialists discuss adverse events associated with T-DXd, focusing on monitoring for interstitial lung disease (ILD) and the role of re-challenging patients with T-DXd after resolution of grade 1 ILD.

Overview of DESTINY-Breast06

July 22nd 2024

Aditya Bardia, MD, MPH, shares comprehensive insights on the DESTINY-Breast06 study evaluating T-DXd in HER2-low and HER2 ultra-low metastatic breast cancer, and the panel offers its initial impressions.